Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced the presentation of Phase 1 data and outlined plans for an adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody candidate for the prevention of Lyme disease. The company expects to initiate the Phase 2 study in the first half of 2027, pending agreement with the U.S. Food and Drug Administration (FDA).
TNX-4800 is designed to target Borrelia burgdorferi, the bacterium that causes Lyme disease, and is intended to provide extended protection during tick season. The candidate was licensed from UMass Chan Medical School. Tonix highlighted the potential advantages of TNX-4800 over traditional vaccine approaches, noting that there are currently no approved prophylactic options for Lyme disease in the United States.
The Phase 1 data, which were presented at a scientific conference, support the safety and pharmacokinetic profile of TNX-4800. The company believes that a monoclonal antibody approach could offer rapid and sustained protection, which may be particularly beneficial for individuals at high risk of tick exposure. The planned Phase 2 study is expected to be a field trial that will evaluate the efficacy of TNX-4800 in preventing Lyme disease in endemic areas.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure also supports its marketed products for acute migraine, including Zembrace SymTouch and Tosymra.
The company is advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The announcement of Phase 1 data and the planned Phase 2 study for TNX-4800 represents a significant step toward addressing the unmet medical need for Lyme disease prevention. With no currently approved prophylactic options in the U.S., a successful monoclonal antibody could provide a new tool for at-risk populations. The outcome of the Phase 2 study will be closely watched by the medical community and investors alike.
For more information on Tonix Pharmaceuticals and its pipeline, visit the company’s newsroom at https://ibn.fm/TNXP.
